PET in abdominal pathology: Advantages and limitations

Abdominal Imaging

Volumn 31, Issue 2, 2006, Pages 174-181

  Sanchez Salmon A ^a   Barandela Salgado, J ^a   Ruibal Morell, A ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Abdominal; FDG; Oncology; PET

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; 5 HYDROXYTRYPTOPHAN C 11; CARBON 11; CARCINOEMBRYONIC ANTIGEN; CHOLINE; CHOLINE C 11; DOPAMINE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUORODOPAMINE F 18; FLUOROTHYMIDINE F 18; GLUCOSE TRANSPORTER; IMATINIB; SOMATOSTATIN RECEPTOR; TRACER; UNCLASSIFIED DRUG;

ABDOMINAL TUMOR; ADVANCED CANCER; BLADDER CANCER; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER STAGING; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DRUG UPTAKE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GLYCOLYSIS; HUMAN; KIDNEY CANCER; LYMPH NODE METASTASIS; MYOMA; NON SEMINOMATOUS GERMINOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS CANCER; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SIGNET RING CARCINOMA; STOMACH CANCER; SURVIVAL RATE; TESTIS CANCER; TREATMENT RESPONSE; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; YOLK SAC TUMOR;

ABDOMEN; DIGESTIVE SYSTEM NEOPLASMS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; UROGENITAL NEOPLASMS;

EID: 33645389295     PISSN: 09428925     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00261-005-0384-7     Document Type: Conference Paper

References (72)

1. Aide N, Cappele O, Bensadoun H, et al. (2003) Efficiency of 18 F-FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 30:1236-1245
2. Alavi A, Kung JW, Zhuang H (2004) Implications of PET Based molecular imaging on the current and future practice of medicine. Semin Nucl Med 34:56-69
3. Anders S, Eriksson B, Bergstrom M (2004) PET in the diagnosis of neuroendocrine tumors. Ann NY Acad Sci 1014:246-257
4. Barrio JR (2004) Future applications in PET imaging: The development and use of molecular biomarkers. Appl Radiol 33(suppl):1-6
5. Bujenovic S (2004) The role of positron emission tomography in radiation treatment planning. Semin Nucl Med 34:293-299
6. Ca van Kouwen M, Jansen JB, van Goor H, et al. (2004) FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis [abstract]. Eur J Nucl Med Mol Imaging 32:399-404
7. Chang CH, Wu Tsai HC JJ, et al. (2003) Detecting metastatic pelvic lymph nodes by 18F-2-deosiglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int 70:311-315
8. Cohade C, Wahl R (2003) Applications of positron emission tomography /computed tomography image fusion in clinical positron emission tomography - clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med 32:228-237
9. Cook G, Wegner E, Fogelman I, et al. (2004) Pitfalls and artefacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med 34:122-133
10. Cremerius U, Effert PJ, Adam G, et al. (1998) FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 39:815-822
11. Davies JR, Rudd JH, Weissberg PL (2004) Molecular and metabolic imaging of atherosclerosis. J Nucl Med 45:1898-1907
12. De Santis M, Bokemeyer C, Becherer A, et al. (2004) 2-18fluorodeoxi-D- glucose positron emission tomography is a reliable predictor of viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22:1034-1039
13. Delbeke D, Martin WH (2004) PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 34:209-223
14. Delbeke D, Rose D, Chapman WC, et al. (1999) Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 40:1784-1791
15. Delbeke D, Vitola J, Sandler MP, et al. (1997) Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 38:1196-1201
16. Delgado-Bolton R, Fernandez-Perez C, Gonzalez Mate F, et al. (2003) Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 44:1301-1314
17. El-Haddad G, Zhuang H, Gupta N (2004) Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 34:313-329
18. Even-Sapir E, Parag Y, Lerman H, et al. (2004) Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 232:815-822
19. Fernandez F, Drebin J, Linehan D, et al. (2004) Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography (FDG PET). Ann Surg 240:438-450
20. Gayed I, Vu T, Iyer R, et al. (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45:17-21
21. Greven KM, Williams DW, McGuirt WF, et al. (2001) Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23:942-946
22. Grigsby PW, Siegel BA, Dehdashti F, et al. (2004) Posttherapy 18F-fluorodeoxiglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 22:2167-2171
23. Haberkom U, Altman A, Mier W, et al. (2004) Impact of functional genomics and proteinomics on radionuclide imaging. Semin Nucl Med 34:4-22
24. Hadvar S, Conti P (2004). The reproductive tract. Semin Nucl Med 34:262-273
25. Hain SF, O'Doherty MJ, Timothy AR (2000) Fluorodeoxyglucose PET in the initial staging of germ cell tumors. Eur J Nucl Med 27:590-594
26. Hicks RJ, Heriot AHG (2003) The impact of FDG-PET on the primary staging of locally-advanced rectal cancer [abstract]. Mol Imaging Biol 5:188
27. Ilias I, Pack K (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89:479-491
28. Israel O, Keidar Z, Bar-Shalom R (2004) Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med 34:166-179
29. Jadvar H, Kherbache HM, Pinski JK, et al. (2003) Diagnostic role of (F18)-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol 60:395-400
30. Jadvar H, Pinski JK, Conti PS (2003) FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep 10:1485-1488
31. Jerome R (2004) Whole body FDG PET in patients with stage I non-seminomatous germ cell tumours [editorial comment]. J Urol 172:1202
32. Jerusalem G, Beguin Y, Fassote MF, et al. (1999) Whole body positron emission tomography using 18-fluoreoxiglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433
33. Kalra M, Maher M, Fischman A (2004) PET and PET/CT in the evaluation of pancreatic malignancies. Disc PET Imaging 634:1-4
34. Kamel E, Thumshirn M, Truninger K, et al. (2004) Significance of incidental 18-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 45:1804-1810
35. Kang D, White R, Zuger J, et al. (2004) Clinical use of fluorodeoxyglucose F18 positron emission tomography for detection of renal cell carcinoma. J Urol 171:1806-1809
36. Kantorova I, Lipska L, Belohlavek O, et al. (2003) Routine 18F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 44:1784-1788
37. Klose T, Leidl R, Buchmann I, et al. (2000) Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography. Eur J Nucl Med 27:1457-1464
38. 18-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med 44:353-358
39. Lai CH, Huang Kg , See LC, et al. (2004) Restaging of recurrent cervical carcinoma with dual phase 18F-fluoro-2-deoxi-D-glucose positron emission tomography. Cancer 100:544-552
40. Larson SM, Morris M, Gunther I, et al. (2004) Tumor localization of 16beta-18F-fluor-5alpha-dihydrotestosterone versus 18F-FDG in patines with progressive metastatic prostate cancer. J Nucl Med 45:366-373
41. Lin WC, Hung Yeh YC LS, et al. (2003) Usefulness of (18)-F- fluorodeoxyglucose positron emission tomography to detect paraaortic lymph nodal metastases in advanced cervical cancer with negative computed tomography imaging findings. Gynecol Oncol 89:73-76
42. Majhail N S, Urbain JL, Albani JM, et al. (2003) F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 21:3995-4000
43. Maldonado A, Garcia Rico E, Cornide M, et al. (2003) Metabolic Imaging in the suspicion of recurrent ovarian cancer based on elevated tumor marker serum levels. Evidence in 81 patients [abstract]. Mol Imaging Biol 5:190
44. Najjar F, Hustinx R, Jerusalem G, et al. (2001) Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm 16:297-304
45. Orlando LA, Kulasingam SL, Matchar DB (2004) The detection of pancreatic malignancy with positron emission tomography [abstract]. Aliment Pharmacol Ther 20:1063-1070
46. Ortega F, Fernandez Martos C, Poveda A, et al. (2003) The usefulness of FDG PET for staging, restaging, and management of gastrointestinal stromal tumors (GIST) and gastric carcinoma, preliminary study in 36 patients [abstract]. Mol Imaging Biol 5:191
47. Ott K, Ulrich F, Becker K (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21:4604-4610
48. Oyama N, Akiro H, Suzuki Y, et al. (2002) Prognostic value of 2-deoxi-2 (F18) fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 4:99-104
49. Potharaju SP, Hall NC, Hubner F, et al. (2003) The role of FDG PET in management of renal cell carcinoma and prognostic significance [abstract]. Mol Imaging Biol 5:195
50. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 44:1072-1074
51. Rohren E, Turkington T, Coleman E (2004) Clinical applications of PET in oncology. Radiology 231:305-332
52. Ryu SY, Kim MH, Park SY, et al. (2003) Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 44:347-352
53. Saisho H, Yamaguchi T (2004) Diagnostic imaging for pancreatic cancer. Computed tomography, magnetic resonance imaging, and positron emission tomography. Pancreas 28:273-278
54. Schöder H, Larson SM (2004) Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34: 274-292
55. Schot B, Van Imhoff G, Pruim J, et al. (2003) Predictive value of early 18F fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol 123:282-287
56. Shreve P, Anzau Y, Wahl R (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19:61-77
57. Shulkin BL, Thompson NW, Shapiro B, et al. (1999) Pheochromocytomas: imaging with 2-fluorine-18 fluoro-2-deoxy-D-glucose PET. Radiology 212:35-41
58. Shvarts O, Han K, Seltzer M, et al. (2002) Positron emission tomography in urologic oncology. Cancer Control 9:335-342
59. Stahl A, Ott K, Weber WA, Fink U, et al. (2001) Correlation of FDG uptake in gastric carcinomas with endoscopic and histopathological findings. J Nucl Med 42(suppl):78
60. Singh AK, Grigsby PW, Dehdashti F, et al. (2003) FDG PET lymph node staging and survival in patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys 56:489-493
61. Teague B, Morrison C, Court F, et al. (2004) Role of FDG PET in surgical management of patients with colorectal liver metastases. Aust N Z J Surg 74:646-652
62. Torizuka T, Kanno T, Futatsubashi M, et al. (2003) Imaging of gynaecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J Nucl Med 44:1051-1056
63. 18F-FDG PET. J Nucl Med 44:1407-1412
64. Whiteford MH, Whiteford HM, Yee LF, et al. (2000) Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 43:759-767
65. Warburg O (1956) On the origin of cancer cells. Science 123:309-314
66. Williams AD, Cousins C, Soutter WP, et al. (2001) Detection of pelvic lymph node metastases in gynaecologic malignancy: a comparison of CT, MR imaging and positron emission tomography. AJR 177:343-348
67. Yoshida Y, Kurokawa T, Kawahara K, et al. (2004) Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR 182:227-233
68. Yoshioka T, Yamaguchi K, Kubota K (2003) Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 44:690-699
69. Zanzonico P (2004) Positron emission tomography: a review of basic principles, scanner design and performance and current systems. Semin Nucl Med 34:87-111
70. Zhuang H, Poudehnad M, Lambright ES, et al. (2001) Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42:1412-1417
71. Zijlstra J, Hoekstra O, Raijmakers P, et al. (2003) 18 FDG positron emission tomography versus 67 Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin lymphoma. Br J Haematol 123:454-462
72. Zinzani PL, Magagnoli M, Chierichetti F, et al. (1999) The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 10:1181-1184